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Abstract
Background: Delirium is a frequent, costly and morbid problem. No agent has been shown to modify the natural
history of the condition, and current treatments have significant side effects. Prophylactic melatonin in low doses
has been shown to prevent delirium developing. This trial then aims to determine the feasibility of a trial to assess
if melatonin at a moderate dose effectively treats the symptoms of delirium and modifies the natural history,
including abating symptoms after treatment cessation.
Methods/design: Elderly (≥70 years of age) patients admitted to the Royal Melbourne Hospital with delirium, and
not requiring surgery, will be identified from the current practice of the investigators and through referral by other
general medical unit staff. To facilitate this, other staff will be briefed on the project by investigators. Patients will be
recruited with suitable informed and documented consent (person responsible) by the study investigators. They will
receive orally either 5 mg melatonin (18 patients) or placebo (18 patients) nightly for 5 nights (or until discharged).
During treatment, participants will be assessed by study staff using a validated scale of delirium severity (the
Memorial Delirium Assessment Scale), and a validated measure of delirium state (Confusion Assessment
Method) to determine if melatonin decreases the severity or the duration of delirium. Assessment will
continue for a further two days after treatment has ceased, to determine if the treatment causes persisting
abatement of symptoms, and to assess for adverse events.
Discussion: The on-going study described herein will contribute to our knowledge of available treatment
options for elderly inpatients with delirium, where current pharmacological interventions show weak or no
effect on hastening the resolution of delirium. As melatonin is safe, cheap, and potentially effective, it would
be easily implementable in routine practice and could lead to significant outcome benefits for delirious
inpatients.
Trial registration: The trial is registered with the Australia New Zealand Clinical Trials Registry (trial ID:
ACTRN12614000101684) (registered 28/01/2014).
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Background
Delirium is a clinical syndrome of acute onset charac-
terised by fluctuating attention and awareness with a
disturbance in cognition due to the direct physio-
logical consequence of a medical condition, intoxica-
tion, withdrawal, toxin, or multiple aetiologies [1].
Melatonin (N-acetyl-5-methoxytryptamine) is a hor-
mone (and likely neurotransmitter) produced by the
pineal gland in the human brain. It is involved in
sleep/wake cycle regulation. Delirium is a condition
with little research into the underlying mechanism,
but felt to be most commonly related to abnormal-
ities of brain neurotransmitters.
Delirium is a common clinical phenotype with a variety
of potential precipitating factors on the background of
predisposing factors. The clinical phenotype does not ap-
pear to vary with cause [2], and therefore research into the
treatment of delirium can be conducted without reference
to aetiology. An exception is Delirium Tremens, a specific
syndrome caused by withdrawal from chronic alcohol
consumption. This is regarded separately from delirium
and is not the topic of the proposed study.
One common feature of delirium is a disturbance of
the sleep wake cycle [2]. In support of a potential role of
melatonin and disturbance of melatonin metabolism in
delirium, Balan et al. demonstrated that levels of urinary
metabolites of melatonin were altered in delirium, in co-
ordination with the level of psychomotor activity (low in
those with hyperactive delirium, high in hypoactive delir-
ium) [3]. Other studies have shown abnormalities of
tryptophan (from which melatonin is formed) are associ-
ated with postoperative and critical care delirium [4, 5].
Further, case reports of successful melatonin use for the
treatment of delirium have been published [6].
The hypothesis that melatonin might be useful for the
prevention and treatment of delirium has been tested, with
two trials being particularly relevant. Al-Aama et al. rando-
mised 145 recently hospitalised participants in a medical
service to melatonin 0.5 mg nocte or placebo for 14 nights
or discharge [7]. Delirium diagnosis was assessed with the
validated Confusion Assessment Method tool and severity
by the validated Memorial Delirium Assessment Scale
(MDAS). Delirium was clinically and statistically signifi-
cantly reduced in the active treatment group by approxi-
mately 61 %, by 81 % when incident (pre-existing prior to
enrolment) delirium was excluded, and 81 % when demen-
tia and comorbidities were controlled for. By comparison,
no medication has been shown to prevent delirium occur-
rence, and two trials of non-pharmacological treatments
showed reductions in the order of 33 % [7]. Delirium se-
verity (on MDAS) was not significantly different, and sur-
rogate outcomes that would suggest efficacy in treatment
of delirium such as length of stay, restraints and use of
sedatives were also not significantly different.
A second trial examined melatonin 5 mg in prevention
of delirium in elderly patients undergoing hip arthroplasty
and spinal anaesthesia. 222 patients were randomised to
standard treatment, midazolam prior to and post-surgery,
or melatonin 5 mg prior to and post-surgery [8]. Delirium
was assessed based on decline on the Abbreviated Mental
Test from baseline. This methodology has been shown [8]
to be a sensitive but not specific method of delirium de-
tection, and likely inferior to the CAM. Delirium oc-
curred in 16/49 control group participants, and 5/53
melatonin group participants, a 72 % relative risk re-
duction. Although the paper stated melatonin 5 mg
was effective in the treatment of delirium, it was not
clear how it was evaluated, and personal communica-
tion with the author revealed this statement was
based on the clinical impression of psychiatrists
assisting in the management of delirious patients.
In contrast to these two trials, a recently com-
pleted randomised-controlled trial of melatonin 3 mg
in the prevention of delirium after hip fracture did
not show a significant reduction in the incidence of
delirium, nor in the severity of incident delirium [9].
Based on current knowledge, it is plausible that mela-
tonin is useful for the prevention of delirium in elderly
patients, that low dose melatonin does not appear to be
useful for treatment of delirium, and that high dose
melatonin (5 mg) may be effective in the treatment of
delirium. However, this needs to be examined further
before it can be recommended.
When considering the efficacy of melatonin in the treat-
ment (rather than prophylaxis) of delirium, it should be
noted that delirium abatement is regarded purely clinic-
ally. Were this decrease or cessation of symptoms to occur
after cessation of an effective treatment, compared to
standard care, it would constitute evidence of cure. This
could be assessed by following trial participants after ces-
sation of active and placebo treatment.
This paper describes the design of the study, “Moderate
dose melatonin for the abatement and treatment of delir-
ium in elderly general medical inpatients”, a trial currently
in progress.
Methods and design
This trial was designed based on CONSORT guidelines
[10]. For a schematic detailing the layout of the study,
see Fig. 1. Trial procedures are described in Table 1.
Research questions
Primary research question
1. To determine if melatonin of 5 mg nightly for 5
nights decreases the severity of symptoms of
delirium in elderly medical inpatients by evaluation
of the MDAS
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Secondary research questions
1. Abatement of symptoms that continues for 2 further
days after the 5 days of treatment
2. The severity and duration of delirium
3. Reduces falls
4. Reduces pressure areas
5. Reduces the use of rescue medications
(antipsychotics, benzodiazepines)
6. Improves sleep quality as evaluated in Item 10 of the
MDAS
7. Reduces the presence of restraints
End points
Primary
1. Change in MDAS score from baseline to average
over days 1–5
Secondary
1. Change in MDAS score from average over days 1–5
to average over days 6–7
2. Presence or absence of delirium from days 1–7 as
assessed by CAM criteria
3. Number of falls over days 1–5 of the study period
4. Number of pressure areas developing over days 1–5
of the study period
5. Number and dose of rescue medications used over
days 1–5 of the study period
6. Change in score on item 10 of the MDAS
7. Number of instances of the use of restraints over
days 1–5 of the study period
Location and setting
The Royal Melbourne Hospital in Parkville, Australia. It
is a major teaching hospital with over 60,000 emergency
attendances and over 85,000 patient admissions a year
into 330 acute beds [11].
Study population and recruitment
During multidisciplinary meetings and the day-to-day
duties of investigators, potential patients will be consid-
ered for inclusion. Patients with a diagnosis of delirium
via the CAM and who are 70 years or older as general
medical inpatients will be screened according to exclu-
sion criteria. These exclusion criteria include solely
hypoactive delirium (MDAS question 9), planned sur-
gery, the inability to speak or understand English, severe
sensory impairment or dysphasia, an expected prognosis
Fig. 1 Overview of the study protocol
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or discharge of less than 7 days, severe hepatic failure
(defined as Bilirubin ≥2.5 times upper limit of normal;
alkaline phosphatase, aspartate transaminase and/or ala-
nine transaminase > 3 times upper limit of normal), a
markedly non-therapeutic INR (<1 or >4), use of mela-
tonin or melatonin receptor agonist in the preceding
14 days, active seizure disorder (a seizure in the last
month, or a seizure disorder not on anticonvulsants),
and concomitant cimetidine use. As melatonin is a seda-
tive medication, it’s clinically inappropriate to provide
this to patients who have an exclusively hypoactive delir-
ium as this may exacerbate the decreased conscious
state. Also, as per Balan et al. [3], an exclusively hypoac-
tive delirium may be associated with an elevated mela-
tonin level. Patients who have surgery planned during
the study period are to be excluded as surgery and an-
aesthesia are independent risk factors for delirium and
would act as intra-intervention confounders.
Given patients with delirium are unable to provide in-
formed consent, consent will be obtained by the person
responsible for surrogate decision making and docu-
mented on clear consent forms. The surrogate decision
maker retains the capacity to withdraw the patient from
the trial at any time. If during the course of the trial the
patient regains capacity due to the resolution of their de-
lirium, a separate informed consent will be obtained
should the patient wish to continue; if they do not, they
will be withdrawn from the trial.
The Melbourne Health Human Research and Ethics
Committee has evaluated and approved this trial.
Randomisation & blinding
After enrolment, patients will be randomised into treat-
ment groups by drawing a sealed, opaque envelope from
a box containing an allocation code (randomised by an
unrelated statistician). The box contains equal numbers
of allocation codes to a total of the expected number of
participants. The envelope and code are discarded after
being drawn. The envelopes will be in permuted blocks
of 4 (2 placebo 2 active).
The results of this randomisation are not known to
any of the investigators or intervention administration
staff. A separate code interpretation sheet is kept locked
in the trial pharmacy, where after the completion of data
collection the allocation codes will be matched to pro-
vide the requisite placebo vs intervention information.
Study medication and administration
Study medication tablets appear identical and are pack-
aged in HDPE containers of 5 capsules each. They are
prepared in accordance with Good Manufacturing Pro-
cedure (GMP) guidelines. On prescription by Medically
qualified research staff, a container may be collected
from the trial pharmacy upon inclusion of a patient. The
medication was purchased through an unrestricted grant
from Healthe Care Australia Pty Ltd. The medication is
prescribed and administered as per the regular drug
chart protocol at our institution, where it is marked as
‘nocte’. As such, to mirror normal practice, it is adminis-
tered at approximately 8 pm nightly for five nights.
Data collection
Baseline demographic data and current medication use
(including as needed [PRN]) medications will be re-
corded. Following enrolment, patients will be visited by
trained and qualified research staff every day to collect
data and assess safety.
Delirium will be diagnosed using the Confusion As-
sessment Method (CAM) [12], as the primary outcome
variable. This is a widely used instrument for the detec-
tion of delirium in the acute hospital setting. It has a
sensitivity of 94–100 % and a specificity of 90–95 % and
generates a DSM IV diagnosis of delirium. Duration of
delirium will be recorded in days and delirium consid-
ered to have ceased the day of the last visit at which the
participant was positive on CAM.
Table 1 Schedule of Procedures
Procedure Entry (D0) Daily 1–5
(on treatment)







MMSE ○ ○ ○ ○
Digit Span ○ ○ ○ ○
CAM ○ ○ ○ ○






Presence of Restraints ○ ○ ○
# Falls ○ ○ ○
# Pressure areas b ○ ○ ○
Rescue medication ○ ○ ○
Adverse events ○ ○
Review INR ○c ○c
aIdeally the IQCODE will be measured at entry but can be measured at
any point
bInitial number and location will be recorded at entry in order to derive the
number of new areas at each subsequent visit
cIf participant is on warfarin, we will review the INR that has been performed
every 1–2 days as is standard protocol for acutely unwell inpatients
when warfarinised
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Delirium severity will be measured by the Memorial
Delirium Assessment Scale (MDAS) [13], a validated
scale suitable for use by both skilled clinical and trained
observers, with good internal consistency and inter-rater
reliability. The maximum MDAS score will be used as a
measure of severity.
Comorbidity will be measured by the Charlson scale
(Charlson Comorbidity Index, CMI) [14] from the his-
tory, patient, and/or surrogate; pre-morbid function will
be measured using the Katz Activities of Daily Living
(ADL) [15] index score from their condition two weeks
prior to admission; depression will be measured using
the GDS-15 item scale [16]; cognition will be measured
by the mini-mental state examination (MMSE) [17].
Premorbid cognitive impairment will be determined
both from chart review for a diagnosis of dementia or
other cause of chronic cognitive impairment by a spe-
cialist neurologist, psychiatrist, or geriatrician, and the
administration of the Informant Questionnaire for Cog-
nitive Impairment or Dementia in the Elderly short form
(IQCODE-sf ) [18]. The IQCODE-sf will be completed
with the assistance of primary caregivers.
Motor subtype of delirium does not have a validated
scale and will be assessed by clinical judgement of the
investigators.
Use of rescue medication will be determined from chart
review and recorded by medication and average daily dose
since last visit, and will be sub-stratified as required into
groupings of those with significant anticholinergic activity,
opioids, antipsychotics, and benzodiazepines.
Delirium treatment
All patients will receive care based on current practice
at the Royal Melbourne Hospital, which is based on
standard procedures including behavioural management,
reorientation, and pharmacotherapy when indicated. If a
patient is already on antipsychotic medication, this will
continue throughout the trial.
Power analysis
The primary endpoint is a decrease in MDAS score from
the baseline to the average score across days 1–5 of
treatment. As a pilot trial, one of the feasibility objec-
tives is to obtain the standard deviation for the primary
outcome measure in order to allow a power calculation
to be performed to assist with the development of an ap-
propriately powered trial to test the relevant hypotheses.
As such, no true power calculation can be calculated.
However, a trial of the prophylactic use of melatonin
in a Canadian hospital [7] yielded entry data of an
MDAS score of 11.4 with a standard deviation (SD) of
3.0. A clinically significant change on the MDAS (high-
est possible score of 30, lowest of 0, positively correlated
with severity) of 3 points at 80 % power and a
significance level of 5 % suggests 16 patients per arm. At
a 10 % dropout rate and rounding up, the groups should
be of 18 patients each.
It should be noted that these figures cannot be used to
precisely calculate power, as they use MDAS score at
entry into the trial (not during treatment), and the popu-
lation is significantly different with an average length of
stay of 14 days (around twice that of similar patients at
RMH). While these results provide some guidance that a
trial is possible and relevant group size and power
achievable, a pilot is still required to confirm the exact
numbers needed.
Statistics
Data will be collected for each patient on a daily basis,
up to 7 days following recruitment. The primary and
secondary outcome measures will be compared using
standard statistical methodology. For continuous vari-
ables, results will be compared using a Students’ t-test
with significance set to 0.05 if they are normally distrib-
uted, else a Mann-Whitney or other non-parametric test
will be utilised. Control and treatment group homogen-
eity will be tested with Chi-square statistics. For discrete
outcomes, results will be tested using a Chi-square test.
Risk ratios will be employed where appropriate. The
Hausman specification test will be used to determine
whether the data should be analysed using either fixed
or random effects, though it is expected that a random
and fixed (mixed) effects model will be required.
Extensions to the statistical methods above may be re-
quired depending on what is found once the data is col-
lected and the analysis is begun.
Missing data will be accounted for using the last ob-
servation carried forward method, and all data will be
analysed according to the intention-to-treat principle
primarily (and per-protocol analysis secondarily).
Discussion
A large quantity of both scientific and journalistic litera-
ture has been generated about the increased number of
older persons living worldwide. The risk of developing
delirium increases as one ages. Given that delirium has
significant health costs to patients, as well as being a sig-
nificant financial burden to families and to society, an ef-
fective treatment for delirium would mitigate against
these costs – and no such treatment currently exists. A
pilot RCT was selected to appropriately assess the rele-
vant outcome measures as discussed above, and to gen-
erate data for powering a larger study in the future. Acute
general medical inpatients as a population are at signifi-
cant risk for developing delirium, and are among a group
that we expect to see significant benefit in and for should
delirium treatment/cessation be successful. This, in con-
junction with not excluding patients with dementia,
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should allow for greater external validity of the results,
and also informs the practice for a large proportion of
hospital inpatients.
Our work should allow for further information as to
whether melatonin is able to provide therapeutic as well
as prophylactic benefit, and as a pilot also guide the
powering of further larger trials if they are warranted in
the future.
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